Table 1.
Baseline characteristics by study arm
| Characteristic | NucleomaxX® (n=26) |
TDF switch (n=24) |
|---|---|---|
| Age, years | 48 (41–51) | 48 (43–51) |
| Male sex, % | 86 | 86 |
| Race, % | ||
| White | 57 | 50 |
| African American | 43 | 36 |
| Hispanic | 0 | 9 |
| Asian | 0 | 1 |
| Body mass index, kg/m2 | 26.1 (19.0–28.0) | 26.1 (22.0–28.0) |
| Limb fat | 4.4 (2.9–6.3) | 5.5 (3.4–7.0) |
| Phosphate, mg/dl | 3.30 (3.15–3.60) | 3.20 (2.80–3.60) |
| CD4+ T−cell count, cells/mm3 | 578 (439–781) | 532 (334–858) |
| Known duration of HIV, months | 146 (78–184) | 108 (68–183) |
| Receiving stavudine at entry, % | 27 | 17 |
| Receiving zidovudine at entry, % | 73 | 83 |
| Receiving PI at entry, % | 38 | 50 |
| Duration of thymidine | 41 | 79 |
| NRTI, months | (24–86) | (48–86) |
Data presented as median (IQR) unless otherwise indicated. Baseline characteristics were well balanced between study arms. NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir.